108 studies found for:    "Viral hemorrhagic fever"
Show Display Options
Rank Status Study
1 Enrolling by invitation Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities
Conditions: Crimean-Congo Hemorrhagic Fever;   Lassa Fever
Intervention: Drug: Ribavirin (Virazole) Injection
2 Enrolling by invitation Ribavirin for Hemorrhagic Fever With Renal Syndrome
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Drug: Ribavirin
3 Enrolling by invitation Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Drug: Virazole (Ribavirin)
4 Completed Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Conditions: Acquired Bleeding Disorder;   Dengue Haemorrhagic Fever
Interventions: Drug: activated recombinant human factor VII;   Drug: placebo
5 Not yet recruiting Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Condition: Hemorrhagic Fever With Renal Syndrome
Interventions: Biological: HTNV/PUUV DNA vaccine;   Biological: Placebo
6 Completed Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Biological: Vaccine/device combination for prevention of HFRS
7 Recruiting Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms
Conditions: Viral Haemorrhagic Fever;   Dengue Fever
Interventions: Drug: Western Medicine;   Drug: TCM and Western Medicine
8 Completed Experimental Vaccine for Prevention of Ebola Virus Infection
Conditions: Ebola Hemorrhagic Fever;   Ebola Virus Disease;   Ebola Virus Vaccines;   Envelope Glycoprotein, Ebola Virus;   Filovirus
Intervention: Drug: VRC-EBOADV018-00-VP
9 Active, not recruiting Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue
Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus;   Biological: Placebo: NaCl 0.9% solution
10 Completed Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus
Condition: Dengue Hemorrhagic Fever
Interventions: Biological: rDEN1delta30;   Biological: rDEN2/4delta30(ME);   Biological: Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
11 Completed Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus;   Biological: Placebo: NaCl 0.9%
12 Active, not recruiting Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
Conditions: Dengue Virus;   Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Disease
Interventions: Biological: Chimeric dengue serotypes (1, 2, 3, 4).;   Biological: Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
13 Completed Efficacy and Safety of Dengue Vaccine in Healthy Children
Conditions: Dengue Virus;   Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Diseases
Interventions: Biological: Chimeric tetravalent dengue (serotype 1, 2, 3, 4);   Biological: Inactivated Rabies virus vaccine
14 Completed Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
Conditions: Dengue;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus;   Biological: NaCl 0.9%;   Biological: Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed;   Biological: Meningococcal A+C vaccine
15 Completed A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus;   Biological: OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines;   Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines;   Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)
16 Active, not recruiting Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus;   Biological: DTaP IPV//Hib vaccine;   Biological: Placebo;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal vaccine
17 Completed Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Virus
Intervention: Biological: ChimeriVax™ Tetravalent Dengue Vaccine
18 Completed Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
Conditions: Dengue;   Dengue Hemorrhagic Fever;   Dengue Virus;   Dengue Fever
Interventions: Biological: CYD Dengue Vaccine;   Biological: Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
19 Completed Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
Conditions: Dengue Virus;   Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Diseases
Interventions: Biological: Chimeric dengue serotype 1, 2, 3, and 4;   Biological: Pneumococcal polysaccharide vaccine
20 Enrolling by invitation Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years